Purple Biotech Ltd. American Depositary Shares (PPBT) Stock Price

PPBTStock

$1.65−45.24%52W

Market Cap$2.68M

P/E—

PEG Ratio—

Div yield—

Beta0.29

PPBT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-35.21%

Price vs S&P 500 (4W)-3.60%

VGM Score45.13

Book Value / Share (Quarterly)$0.01

P/TBV (Annual)3.44x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.00

Price vs S&P 500 (YTD)-17.13%

Net Profit Margin (TTM)-2777.90%

EPS (TTM)$-0.02

10-Day Avg Trading Volume0.12M

EPS Excl Extra (TTM)$-0.02

EPS (Annual)$-0.03

ROI (Annual)-264.97%

Net Profit Margin (5Y Avg)-3987.45%

Cash / Share (Quarterly)$0.00

Revenue Growth QoQ (YoY)0.00%

ROA (Last FY)-150.16%

Revenue Growth TTM (YoY)0.00%

EBITD / Share (TTM)$-0.02

ROE (5Y Avg)-85.27%

Operating Margin (TTM)-430.20%

Cash Flow / Share (Annual)$-0.00

P/B Ratio1.12x

P/B Ratio (Quarterly)0.64x

Net Income / Employee (Annual)$-2,638,600

EV / Revenue (TTM)5.49x

Net Interest Coverage (TTM)-0.86x

ROA (TTM)-99.09%

EPS Incl Extra (Annual)$-0.03

Current Ratio (Annual)1.27x

Quick Ratio (Quarterly)1.48x

3-Month Avg Trading Volume1.88M

52-Week Price Return-45.24%

Revenue / Employee (TTM)$100,000

Tangible BV / Share (Quarterly)$0.00

P/S Ratio (Annual)10.87x

Asset Turnover (Annual)0.07x

52-Week High$3.90

Operating Margin (5Y Avg)-3437.90%

EPS Excl Extra (Annual)$-0.03

CapEx CAGR (5Y)-54.63%

Tangible BV CAGR (5Y)-47.48%

26-Week Price Return-23.08%

Quick Ratio (Annual)1.25x

13-Week Price Return0.00%

Total Debt / Equity (Annual)0.03x

Current Ratio (Quarterly)1.48x

Enterprise Value$5.49M

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-59.22%

Revenue / Employee (Annual)$100,000

Pretax Margin (Annual)-567.70%

Cash / Share (Annual)$0.01

3-Month Return Std Dev26.82%

Net Income / Employee (TTM)$-2,602,400

ROE (Last FY)-271.63%

Net Interest Coverage (Annual)-12.74x

EPS Basic Excl Extra (Annual)$-0.03

Total Debt / Equity (Quarterly)0.02x

EPS Incl Extra (TTM)$-0.02

ROI (TTM)-122.48%

P/S Ratio (TTM)10.87x

Pretax Margin (5Y Avg)-3976.65%

Revenue / Share (Annual)$0.05

Tangible BV / Share (Annual)$0.00

Price vs S&P 500 (52W)-42.06%

Year-to-Date Return-9.09%

5-Day Price Return0.00%

EPS Normalized (Annual)$-0.03

ROA (5Y Avg)-56.09%

Net Profit Margin (Annual)-585.00%

Month-to-Date Return0.00%

Cash Flow / Share (TTM)$-0.53

EBITD / Share (Annual)$-0.03

Operating Margin (Annual)-715.60%

LT Debt / Equity (Annual)0.68x

ROI (5Y Avg)-83.63%

LT Debt / Equity (Quarterly)0.56x

EPS Basic Excl Extra (TTM)$-0.02

P/TBV (Quarterly)2.64x

P/B Ratio (Annual)0.83x

Pretax Margin (TTM)-2781.60%

Book Value / Share (Annual)$0.01

Price vs S&P 500 (13W)-3.30%

Beta0.29x

Revenue / Share (TTM)$0.02

ROE (TTM)-123.62%

52-Week Low$1.00

vGradeC

gGradeD

mGradeD

vgmGradeC

PPBT Earnings Surprise History

Q2 25-4.00est. -2.10

Q3 252.90est. -2.60

Q4 25-6.16est. -3.40

Q1 26-2.33est. -0.38

Q2 26-0.41est. -0.98

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
PPBTPurple Biotech Ltd. American Depositary Shares	C	D	D	$1.65
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Purple Biotech Ltd. American Depositary Shares

Purple Biotech is a clinical-stage oncology company developing first-in-class therapies to overcome drug resistance and immune evasion in cancer. NT219, its lead small molecule candidate, targets IRS1/2 and STAT3 survival pathways associated with drug resistance, while CM24, a monoclonal antibody, blocks CEACAM1 to enhance anti-tumor immune response. Together, these programs address critical mechanisms that allow cancer cells to evade treatment.